Last reviewed · How we verify
Plegisol In Plastic Container (CALCIUM CHLORIDE)
Calcium chloride works by replenishing calcium levels in the body, which is essential for maintaining proper muscle and nerve function.
Calcium Chloride, marketed by Pfizer as Plegisol in a plastic container, is a well-established product used primarily for cardiac arrest, competing in a class of calcium-based treatments. Its key strength lies in its mechanism of action, which effectively replenishes calcium levels critical for muscle and nerve function, setting it apart in emergency medical scenarios. The primary risk to the drug's market position is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | CALCIUM CHLORIDE |
|---|---|
| Sponsor | Pfizer |
| Drug class | calcium chloride |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
| First approval | 1971 |
Mechanism of action
PRISMASOL and PHOXILLUM solutions are pharmacologically inactive. The electrolyte concentrations in the solutions are chosen to restore plasma levels to clinically desired concentrations or maintain plasma levels at the desired concentrations.PRISMASOL and PHOXILLUM solutions are used as replacement solution to replace water and electrolytes removed during hemofiltration and hemodiafiltration. Bicarbonate (or precursor lactate) in the solution is used as an alkalinizing buffer to restore acid-base balance to clinically desirable level.
Approved indications
- Cardiac arrest
- Disorder of electrolytes
- Hyperkalemia
- Hypermagnesemia
- Hypocalcemia
- Hypocalcemic tetany
- Hypokalemia
- Hypokalemia Prevention
- Skin Grafting Adjunct
- Surgical Hemostasis Adjunct
Common side effects
- peripheral vasodilatation
- local burning sensation
- moderate fall in blood pressure
- tingling sensations
- calcium taste
- sense of oppression
- heat wave
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- Epigallocatechin Gallate (EGCG) as a Flushing Agent During Full Pulpotomy in Mature Permanent Molars With Irreversible Pulpitis (NA)
- Multi-centre, Open-label, First-in-man Study With Mucopad HA (NA)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plegisol In Plastic Container CI brief — competitive landscape report
- Plegisol In Plastic Container updates RSS · CI watch RSS
- Pfizer portfolio CI